ArticleClinical rheumatology2026
Identification of ferroptosis hub gene cDKN1A relating to immune microenvironment in rheumatoid arthritis via bioinformatic analysis and experimental verification.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionRheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease in which ferroptosis appears to be implicated. This study aimed to identify ferroptosis-related therapeutic targets for RA via a series of bioinformatic analyses and experimental verification. MATERIALS AND
methodsIn the present study, the GSE12021 and GSE55235 datasets were enrolled for subsequent analysis. Ferroptosis-related differentially expressed genes (FRDEGs) in RA were first identified, followed by random forest (RF), support vector machine (SVM), and Weighted Gene Co-Expression Network Analysis (WGCNA). Immune infiltration was analyzed, the hub genes expression was verified via in vitro experiments. Subsequently, the roles of hub genes in ferroptosis and macrophage polarization were determined through cell function experiments.
resultsA total of 24 FRDEGs were screened in RA, and the hub gene CDKN1A was identified. CDKN1A was associated with a variety of immune cells, such as Macrophage. In the synovial tissues and cells of RA patients, CDKN1A was downregulated, concomitant with ferroptosis activation. In normal synovial fibroblasts, knockdown of CDKN1A activated ferroptosis and induced macrophage M1 polarization, which was alleviated by ferroptosis inhibitor Fer-1. Conversely, in MH7A cells (a rheumatoid arthritis synovial fibroblast cell line), overexpression of CDKN1A significantly attenuated ferroptosis, accompanied by decreased M1 polarization.
conclusionThe ferroptosis-induced by CDKN1A low expression in synovial cells mediates the activation of macrophages. CDKN1A represents a novel potential molecular marker for RA immunotherapy. Key Points • Ferroptosis is a key phenotype of rheumatoid synovial cells. • CDKN1A-mediated ferroptosis is closely related to the synovial immune microenvironment in rheumatoid arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.